论文部分内容阅读
应用免疫组化法检测乳腺癌组织中雌激素受体 (ＥＲ)、孕激素受体 (ＰＲ)水平以及癌基因的变化 ,已成为判断内分泌治疗效果和预后的重要指标[1 ] 。作者观察了 32例乳腺浸润性导管癌组织中雌、孕激素状态与原癌基因Ｃ -ｅｒｂＢ - 2蛋白产物的表达 ,并对ＥＲ、ＰＲ和Ｃ -ｅｒｂ
The use of immunohistochemistry to detect the levels of estrogen receptor (ER) and progesterone receptor (PR) and oncogenes in breast cancer has become an important index to judge the efficacy and prognosis of endocrine therapy [1]. The authors observed the status of the estrogen and progesterone hormones and the expression of the protooncogene C-erbB-2 protein in 32 cases of infiltrating ductal carcinoma of the breast, and examined ER, PR, and C-erb.